FEV1 and MRI Ventilation Defect Reversibility in Asthma and COPD by Serajeddini, Hana et al.
Western University 
Scholarship@Western 
Medical Biophysics Publications Medical Biophysics Department 
3-26-2020 
FEV1 and MRI Ventilation Defect Reversibility in Asthma and 
COPD 
Hana Serajeddini 
Rachel L Eddy 
Christopher Licskai 
David G McCormack 
Grace Parraga 
Follow this and additional works at: https://ir.lib.uwo.ca/biophysicspub 
 Part of the Medical Biophysics Commons 
Citation of this paper: 
Serajeddini, Hana; Eddy, Rachel L; Licskai, Christopher; McCormack, David G; and Parraga, Grace, "FEV1 

















FEV1 and MRI Ventilation Defect Reversibility in 
Asthma and COPD 
 
 




Please cite this article as: Serajeddini H, Eddy RL, Licskai C, et al. FEV1 and MRI Ventilation 








This manuscript has recently been accepted for publication in the European Respiratory Journal. It is 
published here in its accepted form prior to copyediting and typesetting by our production team. After 
these production processes are complete and the authors have approved the resulting proofs, the article 




Copyright ©ERS 2019 
 
 
FEV1 and MRI Ventilation Defect Reversibility in Asthma and COPD 
*Hana Serajeddini MD
1,2
, *Rachel L Eddy BEng
1,3
 Christopher Licskai MD
2
, David G 
McCormack MD
2







Division of Respirology, Department of Medicine, 
3
Department of 
Medical Biophysics, Western University, London CANADA 
*contributed equally as first authors 
 
Correspondence to:  
G. Parraga PhD 
Robarts Research Institute 
1151 Richmond St N 
London, Canada 
N6A 5B7 
Telephone: (519) 931-5265 
Email: gparraga@robarts.ca 
 
Running Title: MRI ventilation defect reversibility in asthma and COPD 
 




Take Home Message 
MRI ventilation defect post-bronchodilator reversibility was not always concordant with FEV1 
reversibility in asthma and COPD. MRI VDP may provide enhanced sensitivity to small airway 
response to inhaled medication.  
 
 
To the Editor 
The underlying pathophysiological determinants of asthma and chronic obstructive pulmonary 
disease (COPD) are related in complex ways.  Importantly however, post-bronchodilator FEV1-
reversibility may occur in approximately 50% of COPD patients [1] whilst epidemiological [2] 
and magnetic-resonance-imaging (MRI) studies [3] suggest that in asthmatics, FEV1-reversibility 
may diminish over time.  As compared to patients with asthma or COPD alone, patients with co-
existing asthma and COPD report worse clinical outcomes [4] and increased healthcare costs [5] 






Xe MRI studies have reported clinically relevant post-bronchodilator 
improvements in MRI ventilation defects in patients with asthma [6] and COPD [7], independent 
of FEV1 reversibility.  However, post-bronchodilator FEV1 and MRI reversibility have not been 
rigorously explored together across a wide range of patients with obstructive lung disease.  
Although their etiology has not been ascertained, MRI ventilation defects are thought to be 
related to airway occlusion or remodeling throughout the airway tree while FEV1 is dominated 
by the larger airways.   
 
To better understand bronchodilator reversibility in patients with a diagnosis of asthma or 
COPD, we retrospectively evaluated spirometry and hyperpolarised 
3
He MRI measurements in 
participants with asthma (age≥40-years, <1 pack-year smoking-history) and COPD (age 60-85-
years, >10 pack-years smoking-history).  We expected that MRI would detect post-
bronchodilator reversibility in participants in whom there was negligible post-bronchodilator 
FEV1-reversibility, thereby providing a small and large-airway quantitative functional 
 
 
measurement with enhanced sensitivity to small airways disease and greater dynamic range than 
FEV1. 
 
We retrospectively evaluated 58 participants including 45 participants with asthma (20 male/25 
female never-smokers, 54±8-years) and 13 with COPD (7 male/6 female ex-smokers, 70±6-
years, 45±17-pack-years) who underwent a single two-hour visit consisting of spirometry and 
MRI before and after inhalation of salbutamol (4x100µg Teva Novopharm Ltd., Toronto, 
Canada) using a pressurised metred-dose inhaler and AeroChamberPlus spacer (Trudell Medical 
International, London, Canada).  Spirometry was performed (MedGraphics, St. Paul, USA) and 
post-bronchodilator reversibility assessed according to guidelines [8].  Participants withheld 
short-acting β-agonists for 6-hours and long-acting β-agonists for 12-hours before their visit.  
Anatomical proton and hyperpolarised 
3
He ventilation MRI were acquired after inhalation from 
functional residual capacity as previously described [9].  We used the minimal clinically-
important-difference (MCID) of 110mL/2% [9] as the threshold for a clinically relevant post-
bronchodilator change in MRI ventilation-defect-percent (VDP) [9].   
 
In asthma, 51% (23/45) of participants were FEV1-reversible, whereas 15% (2/13) of COPD 
participants were FEV1-reversible.  Shown in Figure 1 (bottom panel), COPD and asthma 
participants were further classified into eight subgroups based on FEV1 and VDP post-
bronchodilator reversibility where cyan represents both FEV1 and VDP reversibility, purple 
represents either FEV1 or VDP reversibility and rose reflects neither FEV1, nor VDP 
reversibility.  Twenty-seven percent (12/45) of asthmatics and 15% (2/13) of COPD participants 
exhibited both FEV1 and VDP reversibility (cyan).  As shown in rose, in 33% (15/45) of 
 
 
participants with asthma and 62% of participants with COPD (8/13, ~double the proportion of 
asthmatics) there was neither FEV1 nor VDP-reversibility.  Shown in purple, 24% (11/45) of 
asthmatics and no COPD participants demonstrated FEV1 reversibility in the absence of VDP 
reversibility whilst 16% (7/45) of asthmatics and 23% (3/13) of COPD participants demonstrated 
VDP reversibility in the absence of FEV1 reversibility.  Overall, VDP was greater in participants 
with COPD compared with asthma (pre-bronchodilator 24±9% vs 10±8%, p<0.0001), although a 
similar proportion of participants with COPD and asthma exhibited VDP reversibility (5/13 or 
38% COPD; 19/45 or 42% asthma).  Figure 1 also shows participant demographics and pre- and 
post-bronchodilator hyperpolarised 
3
He static ventilation MRI, for representative participants 
with both FEV1 and VDP reversibility, and with VDP reversibility alone. There was visually and 
quantitatively improved ventilation post-bronchodilator even in participants who did not report 
FEV1 improvements.   
 
We observed a mixture of concordant and discordant FEV1 and MRI VDP reversibility in 
asthmatic and COPD participants and were not surprised that nearly double the proportion of 
participants with asthma reported concordant FEV1 and VDP reversibility (27% versus 15% in 
COPD).  We were surprised that nearly the same proportion of asthmatics reported neither FEV1 
nor VDP reversibility (33%) which was about half the proportion of COPD (62%) reporting the 
same.  FEV1 reversibility in asthma may diminish over time, independent of smoking [2], and 
therefore asthmatics may develop fixed obstruction in a mechanistically different way as 
compared to COPD patients with post-bronchodilator reversibility [10, 11].  VDP was previously 
shown to be an independent predictor of future bronchodilator reversibility in asthmatics [3] and 




We also observed post-bronchodilator FEV1 and MRI ventilation improvements in a small 
number of COPD patients, consistent with previous findings [7].  It is important to note that the 
COPD participants studied here had no previous history of asthma, and may not meet current 
asthma-COPD overlap definitions [10, 11].  VDP is temporally persistent and reproducible in 
COPD [12], so it is possible that corresponding FEV1 and MRI VDP post-bronchodilator 
improvements identify new phenotypes.  Future studies in COPD patients with modest FEV1 and 
VDP reversibility may show that these patients share similarities with asthma and might benefit 
from asthma-targeted therapies.  
 
Perhaps most enlightening was the observation in seven asthmatics and three COPD participants 
who reported reversible VDP in the absence of FEV1 reversibility.  This finding lends credence 
to the growing understanding that FEV1 and VDP are measuring different but complementary 
pathologies.  Given that VDP is more sensitive to small airways disease than FEV1 and VDP 
predicts future bronchodilator reversibility [3], the lack of VDP reversibility demonstrated in 
16% of the asthma participants studied here may be an early indicator of progression to fixed 
obstruction [2], that may stem from suboptimal treatment, inflammation, mucus plugging or 
terminal airway obliteration.  We note that two of these seven participants exhibited a post-
bronchodilator FEV1 improvement >+200 mL but did not meet the 12% threshold (230mL/9%, 
260mL/11%) to satisfy ATS/ERS criteria [8].  The remainder reported post-bronchodilator 
changes in FEV1 of -70mL/-4%, 160mL/6%, -50mL/-5%, 130mL/6% and 140mL/10%; some of 
these post-bronchodilator changes are within the measurement error of FEV1 [8].  Whilst 11 
asthmatics reported FEV1 reversibility with no VDP reversibility, all FEV1-reversible COPD 
 
 
participants also reported VDP-reversibility.  Different VDP and FEV1 responses in COPD and 
asthma may be due to differences in large central airway obstruction and small airways disease 
that is not detected using spirometry.  Previous work showed that MRI in combination with 
oscillometry revealed that VDP was related to total respiratory system and small airways 
resistance before bronchodilator inhalation in asthma but was related only to small airways 
resistance post-bronchodilator in asthma and COPD [13].  This supports the notion that 
bronchodilator acts on the large airways in asthma, which could explain why so many 
participants with asthma but none with COPD showed FEV1 reversibility with no VDP response.  
These findings challenge us to reflect on the pathophysiological processes related to the distal or 
peripheral airways which appear to dominate in COPD, but not asthma.  
 
Our current understanding is that there are different asthma and COPD phenotypes with 
distinctive pathophysiologies, including different contributions of the small and large airways 
[1].  It was not unexpected that FEV1 and VDP reversibility were not always in agreement, 
especially because VDP reflects both the small and large airways [14] and FEV1 measurements 
are dominated by the large airways [15].  Importantly, VDP was not reversible in the majority of 
participants (34/58 total).  This is important to consider in small airways-disease-predominant 
phenotypes, in whom reversibility may not be detected using spirometry, and this may be 
considered for inhaled therapy response in general for patients with asthma and COPD.  If 
inhaled mediations are unable to reach the small airways, this could explain why only a subset of 
patients experience improvements in symptoms or exacerbation frequency.  VDP may provide a 
new way to quantify small and large-airway function with enhanced sensitivity to small airways 
disease and greater dynamic range than FEV1.  Our results suggest the possibility for MRI VDP 
 
 
to provide added value for assessing response to inhaled treatments, and perhaps demonstrate 
different responses for inhalers specifically targeted at the small airways.  VDP responses likely 
depend on patient phenotype and the type of inhaled medication, and this opens the door for 
future investigations to predict which patients will exhibit a VDP response to which inhaled 
medication, in an effort to deliver personalised treatment. 
 
We acknowledge that post-bronchodilator response remains controversial in patients with asthma 
and COPD [11], and this limits the generalisability of our findings.  Whilst age and smoking-
history were clearly different between groups, other parameters considered as key asthma and 
COPD features [10, 11] including airway inflammation, age of disease-onset and/or disease 
duration will be important to consider in future studies.   
 
Post-bronchodilator MRI ventilation defect and FEV1 responses are not always concordant in 
participants with asthma and COPD, suggesting that VDP may provide a more sensitive tool to 
measure response to treatment in the small airways and identify the need for a change in 
treatment.   
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Age years 54 (8)
Female n (%) 25 (56)
FEV1 %pred 65 (19)/75 (20)
FVC %pred 81 (15)/85 (14)
FEV1FVC % 62 (13)/68 (13)
VDP % 10 (8)/7 (7)
ΔFEV1/ΔVDP mL +300 (260)/-150 (190)
COPD n=13 Pre/PostBD
Age years 70 (6)
Female n (%) 6 (46)
FEV1 %pred 47 (12)/51 (14)
FVC %pred 82 (12)/83 (12)
FEV1FVC % 43 (9)/45 (9)
VDP % 24 (9)/22 (11)
















Figure 1. FEV1 and MRI VDP Reversibility in Participants with Asthma and COPD.
Centre slice hyperpolarised 3He MRI static ventilation (cyan) co-registered to
anatomical proton (gray-scale) pre- and post-bronchodilator for representative
participants with both FEV1 and MRI ventilation defect percent (VDP) reversibility, and
with VDP reversibility alone. Tables show demographics for asthma and COPD
participants. Cubic illustration shows eight subgroups with proportions of participants in
each based on FEV1 and MRI VDP reversibility, where cyan represents both FEV1 and
VDP reversibility, purple represents either FEV1 or VDP reversibility, and rose
represents neither FEV1 nor VDP reversibility.
